Skip to main content
Top

2021 | OriginalPaper | Chapter

12. Genomic Vaccines for Pandemic Diseases in Times of COVID-19: Global Trends and Patent Landscape

Authors : C. Possas, A. Antunes, A. M. Oliveira, M. Ramos, S. O. R. Schumacher, A. Homma

Published in: Bio#Futures

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

This chapter provides an analysis of global trends in genomic vaccines, a radical innovation breakthrough (RIB), from technological foresight and pandemic preparedness perspectives, crucial in times of COVID-19. From this conceptual framework, the state-of-the-art and technological prospects for these genomic vaccines are examined, based on a search on scientific publications and on patents for the period 2010–2020, presenting the vaccine patent landscape for the period. This search provides an overview of recent breakthroughs in genomic vaccines and two other related RIBs, gene editing and gene therapy, and identifies novel strategies that could positively contribute to the development of future genomic vaccines to pandemic diseases and COVID-19. Our results evidence in the last decade extraordinary advances in genetic approaches, gene editing and gene therapy, and the rapid development of innovative DNA/RNA vaccines for the prevention and immunotherapy of an extensive diversity of diseases, from the neglected infectious ones to cancer therapy. These results highlight the flexibility of vaccine technological platforms, crucial for response to pandemics and COVID-19, including hepatitis B, varicella, chronic obstructive pulmonary disease, autoimmune diseases – systemic lupus erythematosus, lupus nephritis, and autoimmune myasthenia gravis – and finally a new nucleic acid sequence for immunogenicity to SARS-CoV-2.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literature
go back to reference Antunes MSA and Magalhães JL (org.), Patenteamento e prospecção tecnológica no setor farmacêutico [Patenting and technological foresight in the pharmaceutical sector], Rio de Janeiro, Interciência, UFRJ, 2008. Antunes MSA and Magalhães JL (org.), Patenteamento e prospecção tecnológica no setor farmacêutico [Patenting and technological foresight in the pharmaceutical sector], Rio de Janeiro, Interciência, UFRJ, 2008.
go back to reference Arya B, Markham R (2014) Vaccines for protection from and treatment of Alzheimer’s disease. US Patent 2014199338, 10 January 2014 Arya B, Markham R (2014) Vaccines for protection from and treatment of Alzheimer’s disease. US Patent 2014199338, 10 January 2014
go back to reference Bahl K, Bett AJ, Ciaramella G, Espeseth A, Wang D (2018) Respiratory syncytial virus vaccine. WO Patent 2018170260, 15 March 2018 Bahl K, Bett AJ, Ciaramella G, Espeseth A, Wang D (2018) Respiratory syncytial virus vaccine. WO Patent 2018170260, 15 March 2018
go back to reference Benihoud K, Lanzi A, Perricaudet M (2011) Adenovirus vaccine vectors. WO Patent 2012150478, 28 April 2011 Benihoud K, Lanzi A, Perricaudet M (2011) Adenovirus vaccine vectors. WO Patent 2012150478, 28 April 2011
go back to reference Brito L, Chan M, Geall A, O'hagan D, Singh M (2012) Oil-in-water emulsions that contain nucleic acids. WO Patent 2013006834, 6 July 2012 Brito L, Chan M, Geall A, O'hagan D, Singh M (2012) Oil-in-water emulsions that contain nucleic acids. WO Patent 2013006834, 6 July 2012
go back to reference Campino S, Marin-Menendez A, Kemp A, Cross N, Drought L, Otto TD, et al. A forward genetic screen reveals a primary role for Plasmodium falciparum Reticulocyte Binding Protein Homologue 2a and 2b in determining alternative erythrocyte invasion pathways. PLoS Pathog. 2018. https://doi.org/10.1371/journal.ppat.1007436. Campino S, Marin-Menendez A, Kemp A, Cross N, Drought L, Otto TD, et al. A forward genetic screen reveals a primary role for Plasmodium falciparum Reticulocyte Binding Protein Homologue 2a and 2b in determining alternative erythrocyte invasion pathways. PLoS Pathog. 2018. https://​doi.​org/​10.​1371/​journal.​ppat.​1007436.
go back to reference Chaparro R, Low CM, Ross J, Seidel RD (2018) T-Cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof. WO Patent 2019051127, 6 September 2018 Chaparro R, Low CM, Ross J, Seidel RD (2018) T-Cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof. WO Patent 2019051127, 6 September 2018
go back to reference Chen L, Yang C, Liu X (2020a) New nucleic acid sequence used for expressing polypeptide causing immunogenicity to novel coronavirus Sars-Cov-2 by E.G. inducing immune response in human body, generating bioreporters, and regulating gene function. CN Patent 110951756, 23 February 2020. Chen L, Yang C, Liu X (2020a) New nucleic acid sequence used for expressing polypeptide causing immunogenicity to novel coronavirus Sars-Cov-2 by E.G. inducing immune response in human body, generating bioreporters, and regulating gene function. CN Patent 110951756, 23 February 2020.
go back to reference Chen L, Yang C, Liu X (2020b) Vaccine composition useful for preventing severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and inducing immune response in human body, comprises nucleic acid sequence comprising specific base pair sequence. CN Patent 110974950, 5 March 2020. Chen L, Yang C, Liu X (2020b) Vaccine composition useful for preventing severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and inducing immune response in human body, comprises nucleic acid sequence comprising specific base pair sequence. CN Patent 110974950, 5 March 2020.
go back to reference Cheng X, Wang G, Zhang Y, Zhou G (2016) CXCL13 (Chemokine(C-X-C Motif) Ligand 13) DNA vaccine and application thereof. CN Patent 105797147, 7 April 2016. Cheng X, Wang G, Zhang Y, Zhou G (2016) CXCL13 (Chemokine(C-X-C Motif) Ligand 13) DNA vaccine and application thereof. CN Patent 105797147, 7 April 2016.
go back to reference Ciaramella G (2018) Varicella zoster virus (VZV) Vaccine. WO Patent 2018170270, 15 March 2018 Ciaramella G (2018) Varicella zoster virus (VZV) Vaccine. WO Patent 2018170270, 15 March 2018
go back to reference Ciaramella G, John S (2017) Human cytomegalovirus vaccine. WO Patent 2018075980, 20 October 2017 Ciaramella G, John S (2017) Human cytomegalovirus vaccine. WO Patent 2018075980, 20 October 2017
go back to reference Correia BE, Schief WR (2013) Epitope- scaffold immunogens against respiratory syncytial virus (RSV). WO Patent 2013152274, 5 April 2013 Correia BE, Schief WR (2013) Epitope- scaffold immunogens against respiratory syncytial virus (RSV). WO Patent 2013152274, 5 April 2013
go back to reference Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, et al. A DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol. 2011. https://doi.org/10.1128/CVI.00030-11. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, et al. A DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol. 2011. https://​doi.​org/​10.​1128/​CVI.​00030-11.
go back to reference Fang Z, Wang Y, Fang H, Xu Q, Wu J, Zhang B, Wang H, Tao R, Xie D (2014) Simple and convenient method for preparing periodic Brugia malayi M29 epitope gene protein vaccine. CN Patent 106344914, 5 November 2014. Fang Z, Wang Y, Fang H, Xu Q, Wu J, Zhang B, Wang H, Tao R, Xie D (2014) Simple and convenient method for preparing periodic Brugia malayi M29 epitope gene protein vaccine. CN Patent 106344914, 5 November 2014.
go back to reference Fotin-Mleczek M, Fiedler K, Kowalczyk A, Heidenreich R (2018) Cancer RNA-Vaccine. WO Patent 2017EP66676, 3 July 2018 Fotin-Mleczek M, Fiedler K, Kowalczyk A, Heidenreich R (2018) Cancer RNA-Vaccine. WO Patent 2017EP66676, 3 July 2018
go back to reference Gao H, Qin L, Wang X, Qi X, Wang Y, Gao Y (2012) DNA vaccine for expressing avian reticuloendotheliosis virus gp90 gene as well as establishment method and application of gene. CN Patent 102988969, 28 November 2012. Gao H, Qin L, Wang X, Qi X, Wang Y, Gao Y (2012) DNA vaccine for expressing avian reticuloendotheliosis virus gp90 gene as well as establishment method and application of gene. CN Patent 102988969, 28 November 2012.
go back to reference Glanville JE (2013) Epitope focusing by variable effective antigen surface concentration. WO Patent 2013177214, 21 May 2013 Glanville JE (2013) Epitope focusing by variable effective antigen surface concentration. WO Patent 2013177214, 21 May 2013
go back to reference Heidenreich R, Fiedler K, Fotin-Mleczek M, Kowalczyk A, Elbers K, Wurm M (2018) RNA vaccine and immune checkpoint inhibitors for combined anticancer therapy. WO Patent 2017EP56427, 16 March 2018 Heidenreich R, Fiedler K, Fotin-Mleczek M, Kowalczyk A, Elbers K, Wurm M (2018) RNA vaccine and immune checkpoint inhibitors for combined anticancer therapy. WO Patent 2017EP56427, 16 March 2018
go back to reference Homma A & Possas C (2020) Desenvolvimento e produção da vacina SARS-CoV-2. Notas complementares (Development and production of SARS-CoV-2 Vaccine. Complementary Notes) In Homma A, Possas C, Noronha JC, Gadelha P. Vacina e Vacinação no Brasil: Horizontes Para Os Próximos 20 Anos (Vaccine and Vaccination in Brazil: Horizons for the next 20 years). Edições Livres 2020, Rio de Janeiro. Homma A & Possas C (2020) Desenvolvimento e produção da vacina SARS-CoV-2. Notas complementares (Development and production of SARS-CoV-2 Vaccine. Complementary Notes) In Homma A, Possas C, Noronha JC, Gadelha P. Vacina e Vacinação no Brasil: Horizontes Para Os Próximos 20 Anos (Vaccine and Vaccination in Brazil: Horizons for the next 20 years). Edições Livres 2020, Rio de Janeiro.
go back to reference Hu Y, Sun L, Sun Y (2012) Streptococcus Iniae Trivalent DNA vaccine and construction method thereof. CN Patent 102716499, 16 May 2012. Hu Y, Sun L, Sun Y (2012) Streptococcus Iniae Trivalent DNA vaccine and construction method thereof. CN Patent 102716499, 16 May 2012.
go back to reference Jia R, Wang W, Wang Y, Xu Y, Zhang L, Yan J, Yu J, Zhang W (2014) broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine. CN Patent 103948944, 19 May 2014. Jia R, Wang W, Wang Y, Xu Y, Zhang L, Yan J, Yu J, Zhang W (2014) broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine. CN Patent 103948944, 19 May 2014.
go back to reference Jia R, Xu Y, Zhang L, Xiao Y, Yan J, Wang Y, Yu J, Zhu X, Zhang W (2013) Replicon DNA (Deoxyribonucleic Acid) vaccine for treating chronic hepatitis B. CN Patent 103239717, 15 May 2013. Jia R, Xu Y, Zhang L, Xiao Y, Yan J, Wang Y, Yu J, Zhu X, Zhang W (2013) Replicon DNA (Deoxyribonucleic Acid) vaccine for treating chronic hepatitis B. CN Patent 103239717, 15 May 2013.
go back to reference Jiang S, Lu L, Wang Q, Dai Y (2017) HIV vaccine and preparation method thereof. CN Patent 201710431893, 9 June 2017. Jiang S, Lu L, Wang Q, Dai Y (2017) HIV vaccine and preparation method thereof. CN Patent 201710431893, 9 June 2017.
go back to reference Jiao P, Liao M, Song H (2016) H9 subtype bird flu DNA vaccine and preparing method thereof. CN Patent 201610237685, 14 April 2016. Jiao P, Liao M, Song H (2016) H9 subtype bird flu DNA vaccine and preparing method thereof. CN Patent 201610237685, 14 April 2016.
go back to reference Jing Z, Lin G, Qiu C, Zheng F (2012) Brucella deoxyribonucleic acid (DNA) vaccine as well as construction method and application thereof. CN Patent 102772793, 30 May 2012. Jing Z, Lin G, Qiu C, Zheng F (2012) Brucella deoxyribonucleic acid (DNA) vaccine as well as construction method and application thereof. CN Patent 102772793, 30 May 2012.
go back to reference Kyutoku M, Nakagami H, Koriyama H, Nakagami F, Morishita R (2016) DNA vaccine containing specific epitope of apolipoprotein (A). US Patent 20160303211, 1 July 2016 Kyutoku M, Nakagami H, Koriyama H, Nakagami F, Morishita R (2016) DNA vaccine containing specific epitope of apolipoprotein (A). US Patent 20160303211, 1 July 2016
go back to reference Legarreta Solaguren L, De La Fuente Martínez I, Martínez Fernández L, Milanic, M (2014) Method for designing a vaccine. WO Patent 2015082745, 2 December 2014 Legarreta Solaguren L, De La Fuente Martínez I, Martínez Fernández L, Milanic, M (2014) Method for designing a vaccine. WO Patent 2015082745, 2 December 2014
go back to reference Li J, Cao J, Liu X, Li L, Liu Y (2018) Vibrio mimicus oral target epitope gene vaccine and preparation method and application thereof. CN Patent 20181060036, 22 January 2018. Li J, Cao J, Liu X, Li L, Liu Y (2018) Vibrio mimicus oral target epitope gene vaccine and preparation method and application thereof. CN Patent 20181060036, 22 January 2018.
go back to reference Li Y, Liu N, Wang Y, Zhang L, Xiao Y, Yan J, Yu J, Zhang W, Tian R (2014) Reproducible kidney cancer therapeutic DNA vaccine. CN Patent 103948943, 19 May 2014. Li Y, Liu N, Wang Y, Zhang L, Xiao Y, Yan J, Yu J, Zhang W, Tian R (2014) Reproducible kidney cancer therapeutic DNA vaccine. CN Patent 103948943, 19 May 2014.
go back to reference Liao Y, Chen X, Wu H, Qiu Z, Liao M (2019) Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof. CN Patent 109663124, 14 February 2019. Liao Y, Chen X, Wu H, Qiu Z, Liao M (2019) Chimeric bivalent blood-pressure-reduction vaccine for human vascular smooth muscle cell L-type calcium channels and angiotensin 1-type receptors and application thereof. CN Patent 109663124, 14 February 2019.
go back to reference Liu W, Wu X, Xu L, Yang Z (2013) Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine. CN Patent 201310405991, 9 September 2013. Liu W, Wu X, Xu L, Yang Z (2013) Tumor nucleic acid vaccine based on tissue factor as well as preparation method and application of vaccine. CN Patent 201310405991, 9 September 2013.
go back to reference Lubenau H (2016) Novel Cmv Pp65 targeting DNA vaccine for cancer immunotherapy. EP Patent 20150001802, 16 June 2016 Lubenau H (2016) Novel Cmv Pp65 targeting DNA vaccine for cancer immunotherapy. EP Patent 20150001802, 16 June 2016
go back to reference Lubenau H (2017) Process for the production of a DNA vaccine for cancer immunotherapy. EP Patent 20160001550, 12 July 2017 Lubenau H (2017) Process for the production of a DNA vaccine for cancer immunotherapy. EP Patent 20160001550, 12 July 2017
go back to reference Lubenau H (2018) Novel Pd-L1 targeting DNA vaccine for cancer immunotherapy. EP Patent 20170161666, 16 March 2018 Lubenau H (2018) Novel Pd-L1 targeting DNA vaccine for cancer immunotherapy. EP Patent 20170161666, 16 March 2018
go back to reference Lubenau H (2019) Neoantigen targeting DNA vaccine for combination therapy. EP Patent 20180192782, 4 September 2019 Lubenau H (2019) Neoantigen targeting DNA vaccine for combination therapy. EP Patent 20180192782, 4 September 2019
go back to reference Markham R (2013) Methods and compositions for preventing a condition. WO Patent 2014028644, 14 August 2013 Markham R (2013) Methods and compositions for preventing a condition. WO Patent 2014028644, 14 August 2013
go back to reference McCoy JR, Mendoza JM, Spik KW, Badger C, Gomez AF, Schmaljohn CS, et al. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2014. https://doi.org/10.4161/hv.29671. McCoy JR, Mendoza JM, Spik KW, Badger C, Gomez AF, Schmaljohn CS, et al. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2014. https://​doi.​org/​10.​4161/​hv.​29671.
go back to reference Morishita R, Nakagami H, Koriyama H, Nakagami F, Yoshida N (2012) DNA Vaccine. US Patent 20140099335, 13 April 2012 Morishita R, Nakagami H, Koriyama H, Nakagami F, Yoshida N (2012) DNA Vaccine. US Patent 20140099335, 13 April 2012
go back to reference Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015. https://doi.org/10.1126/scitranslmed.aac7462. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015. https://​doi.​org/​10.​1126/​scitranslmed.​aac7462.
go back to reference Nakagami H, Kyutoku M, Morishita R, Tomioka H (2013) DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope. US Patent 20150202271, 28 August 2013 Nakagami H, Kyutoku M, Morishita R, Tomioka H (2013) DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope. US Patent 20150202271, 28 August 2013
go back to reference Shan J, Du Y, Cheng G, Jia P, Liu H, Wang Y, Xu Q, Wei J (2015) Application of chitosan oligosaccharide in preparing vaccine adjuvant and vaccine composition. CN Patent 104906574, 25 June 2015. Shan J, Du Y, Cheng G, Jia P, Liu H, Wang Y, Xu Q, Wei J (2015) Application of chitosan oligosaccharide in preparing vaccine adjuvant and vaccine composition. CN Patent 104906574, 25 June 2015.
go back to reference Smietanka K, Florys K, Gora-Sochacka A, Gromadzka B, Minta Z, Sanczyafska V, Sirko A, Stachyra A, Szewczyk B, Zagorski-Ostoja W, Saczynska V, Sawicka R, Bednarczyk M, Lakota P, Asmietanka K, Zagorski-Ostoja WW (2012) DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine. US Patent 20140255343, 21 September 2012 Smietanka K, Florys K, Gora-Sochacka A, Gromadzka B, Minta Z, Sanczyafska V, Sirko A, Stachyra A, Szewczyk B, Zagorski-Ostoja W, Saczynska V, Sawicka R, Bednarczyk M, Lakota P, Asmietanka K, Zagorski-Ostoja WW (2012) DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine. US Patent 20140255343, 21 September 2012
go back to reference Sun L, Li M (2015) Application of turbot CD83 molecules serving as vaccine adjuvant. CN Patent 104689313, 4 March 2015. Sun L, Li M (2015) Application of turbot CD83 molecules serving as vaccine adjuvant. CN Patent 104689313, 4 March 2015.
go back to reference Sun L, Zhang J (2013) Application of heat shock protein 70 as immunoadjuvant. CN Patent 103405763, 15 July 2013. Sun L, Zhang J (2013) Application of heat shock protein 70 as immunoadjuvant. CN Patent 103405763, 15 July 2013.
go back to reference Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020.
go back to reference United Nations Development Programme (2016). 2030 Sustainable Development Goals. United Nations, Geneva. United Nations Development Programme (2016). 2030 Sustainable Development Goals. United Nations, Geneva.
go back to reference Wang Y, Wu H, Xu Y, Zhang L, Yan J, Yu J, Zhu X, Zhang W (2013) Fermentation medium and method for producing plasmid DNA vaccine pSVK-CAVA for treatment of melanoma by fermentation medium. CN patent 103952367, 16 April 2013. Wang Y, Wu H, Xu Y, Zhang L, Yan J, Yu J, Zhu X, Zhang W (2013) Fermentation medium and method for producing plasmid DNA vaccine pSVK-CAVA for treatment of melanoma by fermentation medium. CN patent 103952367, 16 April 2013.
go back to reference Warnke P, Cuhls K, Schmoch, Daniel L, Andreescu et al. 100 Radical Innovation Breakthroughs for the Future, 2019. Warnke P, Cuhls K, Schmoch, Daniel L, Andreescu et al. 100 Radical Innovation Breakthroughs for the Future, 2019.
go back to reference Wu TC, Hung C (2013) Use of Ar-42 Enhances E7-Specific Cd8+ T-Cell mediated antitumor immunity in conjunction with DNA vaccine. US Patent 201261731225p, 27 November 2013 Wu TC, Hung C (2013) Use of Ar-42 Enhances E7-Specific Cd8+ T-Cell mediated antitumor immunity in conjunction with DNA vaccine. US Patent 201261731225p, 27 November 2013
go back to reference Xi Y, Luo Y (2011) Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof. CN Patent 102161998, 14 January 2011 Xi Y, Luo Y (2011) Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof. CN Patent 102161998, 14 January 2011
go back to reference Xu Y, Wang L, Zhang L, Yan J, Yu J, Zhu X, Zhang W, Du Z, Wang Y (2013) Vector PSVK based hepatitis B therapeutic plasmid DNA vaccine fermentation production method, and special engineering bacterium and high-yield fermentation culture medium therefor. CN Patent 103396975, 15 May 2013. Xu Y, Wang L, Zhang L, Yan J, Yu J, Zhu X, Zhang W, Du Z, Wang Y (2013) Vector PSVK based hepatitis B therapeutic plasmid DNA vaccine fermentation production method, and special engineering bacterium and high-yield fermentation culture medium therefor. CN Patent 103396975, 15 May 2013.
go back to reference Yongzhi X, Yuan L (2011) Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof. CN102161998, filed January 14, 2011 Yongzhi X, Yuan L (2011) Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof. CN102161998, filed January 14, 2011
Metadata
Title
Genomic Vaccines for Pandemic Diseases in Times of COVID-19: Global Trends and Patent Landscape
Authors
C. Possas
A. Antunes
A. M. Oliveira
M. Ramos
S. O. R. Schumacher
A. Homma
Copyright Year
2021
DOI
https://doi.org/10.1007/978-3-030-64969-2_12